Treatment

Arexvy powder and suspension for suspension for injection clinical trials

3 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (≥18 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses and compared to healthy controls (≥50 years of age) receiving 1 dose
This study is looking at a new vaccine to protect people who have had lung or kidney transplants from a common bug called RSV. We want to see how well the vaccine works and if it's safe, by giving one or two doses and comparing it to healthy people.
For: Respiratory Syncytial Virus Infections
Spain · Italy · Germany
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above.
This study is looking at a new vaccine for RSV (a common cold-like virus) in people aged 50 and over. It's testing if it works well and is safe when given at the same time as an updated COVID-19 vaccine.
For: Respiratory Syncytial Virus Infections
Spain · Belgium · Netherlands
Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3, randomized, controlled, partially blind, immuno-bridging study to evaluate immunogenicity, reactogenicity, safety and the occurrence of RSV-associated respiratory tract illness after administration of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults aged 60 years and older.
This study is testing a new vaccine for older adults against a common chest infection called RSV. It looks at how well the vaccine works, if it causes side effects, and how safe it is for people aged 60 and over.
For: Respiratory Syncytial Virus Infections
Finland · Poland · Spain

A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above.